csf1r in 2

CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).

Axl Mer CSF1R-IN-2 (Comp 4) serves as an inhibitor for Axl, Mer, and CSF1R [1].

PLX5622 hemifumarate is a highly selective, brain-penetrant, and orally active CSF1R inhibitor with an IC50 of 0.016 μM and Ki of 5.9 nM. It allows for extended and specific microglial elimination preceding and during pathology development and demonstrates desirable PK properties in various animals [1] [2].

Sulfatinib (KDR-IN-1) (HMPL-012) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1 2 3, FGFR1 and CSF1R with IC 50 s ranging from 1 to 24 nM.

Cabiralizumab (FPA 008), an anti-CSF1R monoclonal antibody (MAb), promotes T cell infiltration and boosts antitumor immune responses. It also prevents osteoclast activation, thereby inhibiting bone destruction, and is utilized in rheumatoid arthritis (RA) research. Additionally, Cabiralizumab can be paired with Nivolumab in lung cancer studies [1] [2].